DALLAS and NEW YORK, March 20, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on financial results for the quarter and the fiscal year ended December 31, 2012. The company will also review ongoing commercial activities and progress made within its MuGard program. MuGard, Access' lead product, is a novel; ready-to-use mucoadhesive oral wound rinse and coating indicated for the management of oral mucositis and stomatitis, debilitating side effects of many anticancer treatments, and all types of oral wounds.
Some the Company's fourth quarter highlights to be discussed on the call include:
- MuGard gross revenues for the quarter ended December 31, 2012 were $1.05 million, an increase of 256% compared to the fourth quarter of 2011;
- Continued growth in the MuGard distribution network through additions of pharmacy wholesalers and specialty pharmacies;
- Signing of a Federal Supply Schedule Agreement with the U.S. Department of Veterans Affairs (VA), a large contract through which federal customers can acquire MuGard directly from commercial suppliers;
- Acceptance by Oncology Nursing Society (ONS) for a presentation of MuGard data at the ONS Congress in April 2013;
- Successfully added Walgreens to its MuGard Pharmacy Benefit Management (PBM) list.
Investor Call Details:
The investor conference call is scheduled to be held on Wednesday, April 3, 2013 at 11:00 am ET. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
A replay of the call will be available starting on April 3, 2013 at 1:00 pm ET, through April 17, 2013 until 11:59 pm ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and conference ID number 377785.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard (www.MuGard.com), which has received FDA-marketing clearance for the management of patients with mucositis, and ProLindac, a second generation DACH platinum drug. The Company also has other advanced drug delivery technologies including CobaCyte-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard and Cobalamin, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Company and Media Contact:
Director of Investor Relations
Access Pharmaceuticals, Inc.
SOURCE Access Pharmaceuticals, Inc.